Kashiv Biosciences近日宣布，已向美国食品药品监督管理局（FDA）提交生物制品许可申请，同时欧洲药品管理局已接受其市场授权申请。此次申请涉及的产品为Adl-018，这是一款拟议的Xolair®（奥马珠单抗）生物类似药。
Kashiv Biosciences近日宣布，已向美国食品药品监督管理局（FDA）提交生物制品许可申请，同时欧洲药品管理局已接受其市场授权申请。此次申请涉及的产品为Adl-018，这是一款拟议的Xolair®（奥马珠单抗）生物类似药。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.